AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
119 hedge funds and large institutions have $294M invested in AMAG Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 50 reducing their positions, and 16 closing their positions.
20% more capital invested
Capital invested by funds: $244M → $294M (+$49.5M)
0% more funds holding
Funds holding: 119 → 119 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
45% less call options, than puts
Call options by funds: $2.4M | Put options by funds: $4.34M
52% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$3.99M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.62M |
| 3 |
Morgan Stanley
New York
|
+$2.35M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
+$1.28M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$11.1M |
| 2 |
Goldman Sachs
New York
|
-$1.79M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.49M |
| 4 |
BlackRock
New York
|
-$959K |
| 5 |
PC
Permanens Capital
New York
|
-$956K |
AMAG Hedge Fund Activity: Q2 2020 in Review
119 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q2 2020, worth a combined $294M — up 20% from $244M a quarter earlier.
Fund positioning in AMAG was balanced in Q2 2020: 16 funds opened new positions, 16 closed out, 24 added to existing stakes and 50 trimmed.
The largest buyer was Bank of America, adding an estimated $3.99M. The largest seller was State Street, cutting an estimated $11.1M.
- 119 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $294M of AMAG Pharmaceuticals stock for Q2 2020, up 20% quarter-over-quarter.
- 16 funds opened new AMAG Pharmaceuticals positions in Q2 2020 and 16 closed out, a net change of 0 holders.
- The largest AMAG Pharmaceuticals buyer in Q2 2020 was Bank of America, an estimated $3.99M added.
- The largest AMAG Pharmaceuticals seller in Q2 2020 was State Street, an estimated $11.1M sold.
Based on aggregated 13F filings for Q2 2020.